John Barnes, MD
Family Medicine · Midlothian, VANPI 1033160114
Payments from drug & device makers
Across 254 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$573
- Novo Nordisk$323
- Takeda Pharmaceuticals U.S.A., Inc.$208
- GSK$200
- Boehringer Ingelheim$132
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,046 |
| Amgen | 36 | $573 |
| Novo Nordisk | 24 | $323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $208 |
| GSK | 15 | $200 |
| Boehringer Ingelheim | 8 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Pfizer | 8 | $109 |
| Astellas Pharma US Inc | 6 | $108 |
| Novartis | 6 | $107 |
| Merck | 6 | $101 |
| AstraZeneca | 7 | $91 |
| Amarin Pharma, Inc. | 4 | $80 |
| Boston Scientific | 2 | $63 |
| Lilly USA, LLC | 5 | $62 |
| Medtronic | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Nalpropion Pharmaceuticals LLC | 2 | $37 |
| Genentech USA, Inc. | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Johnson & Johnson | 2 | $26 |
| Scilex Pharmaceuticals Inc. | 2 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Corium, LLC | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Abbott | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,818 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $76,238 |
| EliquisApixaban | 79 | $63,185 |
| OzempicSemaglutide | 31 | $47,996 |
| Repatha SureclickEvolocumab | 36 | $27,213 |
| VascepaIcosapent Ethyl | 24 | $12,982 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,713 |
| XareltoRivaroxaban | 17 | $12,067 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $10,317 |
| Rosuvastatin Calcium | 583 | $9,145 |
| LinzessLinaclotide | 13 | $6,881 |
| Testosterone | 16 | $2,984 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,892 |
| SynthroidLevothyroxine Sodium | 41 | $2,621 |
| Celecoxib | 74 | $2,236 |
| Ezetimibe | 64 | $2,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $132 | $86,55571 claims |
| PfizerEliquis | $109 | $63,18579 claims |
| Novo NordiskOzempic | $323 | $47,99631 claims |
| GSKBreo Ellipta | $200 | $12,71332 claims |
| Johnson & JohnsonXarelto | $26 | $12,06717 claims |
| AbbVieLinzess, Synthroid | $1,046 | $9,50254 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $1,745202 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $24 | $83519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Midlothian
- Aaron HartmanMidlothian$17.4M
- Jennifer BrownMidlothian$1.3M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.